Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

NCT00901901 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

732

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Erlotinib (Tarceva)
DRUG: Placebo

Sponsor

Bayer